At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 316 enrolled
Drug / intervention
Erdafitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
In Brief
A Phase 2 clinical trial evaluating Erdafitinib for Advanced Solid Tumor. Completed, enrolled 316 participants across 179 sites in 15 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) alterations (mutations or gene fusions). It will also evaluate ORR in pediatric participants with advanced solid tumors and FGFR alterations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesArgentina, Australia, Belgium, Brazil, China, France, Germany, Italy, Japan, Poland, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartNov 2019
Primary CompletionDec 2023
Study CompletionFeb 2026
TodayJul 2026
First PostedSep 10, 2019
Enrollment StartNov 20, 2019
Primary CompletionDec 4, 2023
Study CompletionFeb 28, 2026
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 6.8 years ago
Interventions
Erdafitinibdrug
Participants will receive erdafitinib oral tablets.